Suppr超能文献

肾上腺素能机制在双阿司匹林交联血红蛋白升压效应中的作用

Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin.

作者信息

Gulati A, Rebello S

机构信息

Department of Pharmaceutics and Pharmacodynamics (m/c 865), University of Illinois at Chicago 60612.

出版信息

J Lab Clin Med. 1994 Jul;124(1):125-33.

PMID:7913484
Abstract

Diaspirin cross-linked hemoglobin (DCLHB; Baxter Healthcare Corp., Blood Substitutes Division) is a promising hemoglobin-based oxygen-carrying resuscitative solution. DCLHb (400 mg/kg, intravenously) produces an immediate increase in blood pressure when administered to conscious or anesthetized rats. To determine the role of the central nervous system and the peripheral vascular system in the pressor effect of DCLHb, experiments were performed in cervical-sectioned rats. Intravenous administration of DCLHb produced an increase in blood pressure in cervical-sectioned animals (41.2 +/- 2.5 mm Hg), which was similar to that observed in normal rats. To test whether the pressor effect was due to release of catecholamines or other pressor substances from the adrenal medulla, DCLHb was administered to bilateral adrenal demedullated rats. DCLHb was found to produce a pressor effect in bilateral adrenal demedullated rats (42.0 +/- 6.4 mm Hg) that was similar to normal rats. To determine whether DCLHb alters the responsiveness of peripheral vascular adrenoceptors, the effect of DCLHb pretreatment on the blood pressure and heart rate responses of adrenergic agonists was studied. DCLHb significantly potentiated (66.7%) the pressor response to norepinephrine (0.5 to 2.0 microgram/kg, intravenously) but did not affect the heart rate response to norepinephrine. Phenoxybenzamine completely blocked the DCLHb-induced potentiation of the norepinephrine responses. Phenylephrine produced a dose dependent (5 to 20 micrograms/kg, intravenously) pressor and reflex bradycardic effect. DCLHb significantly potentiated the pressor (40.6%) and bradycardiac (-22.8%) effect of phenylephrine, which were completely blocked by prazosin.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

双阿司匹林交联血红蛋白(DCLHB;百特医疗保健公司,血液替代品部)是一种很有前景的基于血红蛋白的携氧复苏溶液。给清醒或麻醉的大鼠静脉注射DCLHb(400毫克/千克)会使血压立即升高。为了确定中枢神经系统和外周血管系统在DCLHb升压作用中的作用,在颈段切断的大鼠身上进行了实验。给颈段切断的动物静脉注射DCLHb会使血压升高(41.2±2.5毫米汞柱),这与在正常大鼠身上观察到的情况相似。为了测试升压作用是否是由于肾上腺髓质释放儿茶酚胺或其他升压物质,给双侧肾上腺去髓质的大鼠注射DCLHb。发现DCLHb在双侧肾上腺去髓质的大鼠身上产生的升压作用(42.0±6.4毫米汞柱)与正常大鼠相似。为了确定DCLHb是否改变外周血管肾上腺素能受体的反应性,研究了DCLHb预处理对肾上腺素能激动剂的血压和心率反应的影响。DCLHb显著增强(66.7%)了对去甲肾上腺素(0.5至2.0微克/千克,静脉注射)的升压反应,但不影响对去甲肾上腺素的心率反应。酚苄明完全阻断了DCLHb诱导的去甲肾上腺素反应增强。去氧肾上腺素产生剂量依赖性(5至20微克/千克,静脉注射)的升压和反射性心动过缓作用。DCLHb显著增强了去氧肾上腺素的升压(40.6%)和心动过缓(-22.8%)作用,这些作用被哌唑嗪完全阻断。(摘要截取自250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验